Product Description
DSP-7888 Dosing Emulsion, also known as ombipepimut-S (United States Adopted Name; International Nonproprietary Name: adegramotide/nelatimotide), is an investigational therapeutic cancer vaccine comprising two synthetic peptides derived from WT1 to promote both cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte-mediated immune responses against WT1-expressing tumors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33939067/)
Mechanisms of Action: Vaccine, WT1
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Glioblastoma
Phase 2: Glioma|Preleukemia|Myelodysplastic Syndrome|Glioblastoma|Peritoneal Cancer|Renal Cell Carcinoma|Fallopian Tube Cancer|Ovarian Cancer|Transitional Cell Carcinoma|Acute Myeloid Leukemia
Phase 1: Myelodysplastic Syndrome|Sarcoma, Myeloid|Pancreatic Cancer|Renal Cell Carcinoma|Acute Myeloid Leukemia|Ovarian Cancer|Melanoma|Non-Small-Cell Lung Cancer|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02498665 |
BBI-DSP7888-101 | P1 |
Completed |
Renal Cell Carcinoma|Acute Myeloid Leukemia|Ovarian Cancer|Melanoma|Pancreatic Cancer|Sarcoma, Myeloid|Myelodysplastic Syndrome|Glioblastoma|Non-Small-Cell Lung Cancer |
2018-08-01 |
16% |
2023-10-18 |
Primary Endpoints|Treatments |
NCT04747002 |
WT1-AM-05 | P2 |
Unknown status |
Acute Myeloid Leukemia |
2024-03-01 |
2024-04-02 |
Primary Endpoints |
|
NCT03311334 |
BBI-DSP7888-102CI | P2 |
Terminated |
Renal Cell Carcinoma|Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer|Transitional Cell Carcinoma |
2022-10-19 |
41% |
2024-04-19 |
Primary Endpoints |
JapicCTI-163216 |
JapicCTI-163216 | P2 |
Unknown |
Glioma |
2020-04-30 |
20% |
||
NCT02436252 |
MDS | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2020-03-01 |
10% |
2022-04-06 |
Primary Endpoints|Treatments |
NCT02750891 |
DB601001 | P2 |
Completed |
Glioblastoma|Glioma |
2020-01-01 |
20% |
2022-04-06 |
Primary Endpoints|Treatments |
NCT03149003 |
WIZARD 201G | P3 |
Completed |
Glioblastoma |
2021-08-30 |
48% |
2023-10-18 |
Primary Endpoints|Treatments |